

CURRICULUM VITAE

Name: Lapo Alinari, M.D., Ph.D.

Current Address: The Ohio State University, Comprehensive Cancer Center,
410 West 12th Avenue, Room 464, Columbus, OH, 43210
Office Phone: (614)-685-9256
Fax: (614)-293-4890
E-mail: Lapo.Alinari@osumc.edu

Licensures: Medical License: State Medical Board of Ohio (active)
DEA License: Drug Enforcement Agency (active)

Education:

May 2011: Ph.D. “Clinical and Experimental Haematology and Haematopathology”,
University of Bologna, Italy.

April 1998: M.D., University of Florence, Italy.

July 1991: High school graduation at Liceo Scientifico “P. Gobetti”, Florence, Italy

Postdoctoral Training:

2013-6/2016: Fellowship in Hematology and Bone Marrow Transplantation, The Ohio State
University College of Medicine, Columbus, Ohio. Participating in the ABIM Research
Pathway.

2011-2013: Internship and Residency, Internal Medicine, The Ohio State University College
of Medicine, Columbus, Ohio. Participated in the ABIM Research Pathway.

2008-2011: Ph.D. in Clinical and Experimental Haematology and Haematopathology,
University of Bologna, Italy.

2006-2008: Visiting Scholar, Comprehensive Cancer Center, The Ohio State University,
Columbus, Ohio. Laboratory of Robert Baiocchi, M.D., Ph.D.

2003-2007: Fellowship in Hematology, Hematology and Medical Oncology Institute “L. e A.
Seràgnoli”, University of Bologna, Italy.

1999-2003: Fellowship in Medical Oncology, Hematology and Medical Oncology Institute
“L. e A. Seràgnoli”, S. Orsola Hospital, Bologna, Italy.

Certifications:

2014-present: Board Certification: Internal Medicine, American Board of Internal Medicine

2016-present: Board Certification: Hematology, American Board of Internal Medicine

Current Position:

-7/1/2016-present: Assistant Professor of Medicine, Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, Ohio

Honors and Awards:

-February 2017: Davis Bremer Award, The Ohio State University

-June 2016: James V. Warren Internal Medicine Fellow Research Award, The Ohio State University

-April 2016: American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award

-November 2015: Lymphoma Research Foundation Clinical Research Mentoring Program Award

-June 2015: 2015 Excellence in Hematology & Oncology Research Award, Division of Hematology and Medical Oncology, The Ohio State University

- July 2014: 2014 AACR Basic Cancer Research Fellowship

-November 2013: 2013 Celgene Award for Future Leaders in Hematology

-June 2013: Clara D. Bloomfield Excellence in Hematology & Oncology Research Award

-June 2013: Chairman's Award for Scholarly Achievement by a Senior Internal Medicine Resident, College of Medicine, The Ohio State University

-October 2012: American Society of Hematology Abstract Achievement Award

-October 2011: American Society of Hematology Abstract Achievement Award

-July 2008: American Society of Hematology-European Hematology Association International Award.

-December 2006: 2007 Italian Society of Experimental Haematology Award

Membership in Professional Societies:

-2013-present: American Society of Clinical Oncology (ASCO)

-2013-present: American Association for Cancer Research (AACR)

-2008-present: American Society of Hematology (ASH)

-2007-present: European Hematology Association (EHA)

Contributions to National/Institutional/Professional Organizations:

-Co-Chair, 2016 American Society of Hematology Meeting, Session: Aggressive Lymphomas (diffuse large B cell and other aggressive B cell non-Hodgkin lymphomas)-Results from prospective clinical trials: CNS and HIV lymphoma trials.

-Invited abstract reviewer, 2016 American Society of Hematology Meeting, Category: Aggressive Lymphomas (diffuse large B cell and other aggressive B cell non-Hodgkin lymphomas)-Results from prospective clinical trials.

-Co-Chair, 2014 American Society of Hematology Meeting, Session: Non-Hodgkin Lymphoma: Biology, excluding Therapy: Molecular Pathogenesis and Prognostic Factors.

-Co-Chair, 2013 American Society of Hematology Meeting, Session: Non-Hodgkin Lymphoma: Biology, excluding Therapy: Novel Prognostic Factors in Non-Hodgkin's Lymphomas.

-Co-Chair, 2013 American Society of Hematology Meeting, Session: Non-Hodgkin Lymphoma: Biology, excluding Therapy: Genetic Signature in Non-Hodgkin's Lymphomas.

-Invited coordinating abstract reviewer, 2013 American Society of Hematology Meeting, Category: Non-Hodgkin Lymphoma: Biology, excluding Therapy

-Co-Chair, 2012 American Society of Hematology Meeting, Session: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents.

-Invited abstract reviewer, 2012 American Society of Hematology Meeting, Category: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents.

-Co-Chair, 2010 American Society of Hematology Meeting, Session: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents.

-Invited abstract reviewer, 2010 American Society of Hematology Meeting, Category: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents.

Mentoring/Advising History:

Time Period as Mentee	Name	Degrees	Position while Mentee	Project	Capacity of Mentoring	Current Position (if known)
2016-	Alessandro Canella	PhD	Postdoctoral Researcher	WNT inhibition in aggressive B-cell Non-Hodgkin's Lymphomas	Research Mentor	Postdoctoral Researcher-OSU
2014-	Vrajesh Karkhanis	PhD	Postdoctoral Researcher	Targeting epigenetic modulators in aggressive B-cell Non-Hodgkin's lymphomas	Research Mentor	Postdoctoral Researcher-OSU

2010-2011	Emily Wilding	MD	Medical Student	Mantle Cell Lymphoma Therapeutics	Research Supervisor	Pathology Resident-U of Maryland
2010-2016	Porsha Smith	BS	PhD Candidate	Characterization of PRMT5 Inhibitors	Research Supervisor	Graduate Research Associate-OSU
2009-2015	Carl Quinion	BS	Undergraduate and Medical Student Researcher	MCL Therapeutics	Research Co-Mentor	Medical Student: WVU
2007-2009	John Ryu	Undergrad	Research Associate	Histone deacetylase inhibition in EBV Lymphomas	Research Supervisor	Diagnostic Radiology Residency
2007-2008	Joline Fan	Undergrad	Undergraduate Researcher	PRMT5 & Epigenetic Control of aggressive B-cell lymphomas	Research Co-Mentor	Medical Student-UCSF

Patents and Technology Transfer:

-US Patent. No. 8,591,892 issued on Nov 26, 2013. Expiration date: 07/18/2032: FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death. First named inventor: Lapo Alinari.

Research Support:

Active

Davis Bremer Award (**PI: Alinari**) 5/1/2017-4/30/2019
\$100,000

Improving Immune targeted therapy in aggressive B-cell Non-Hodgkin's lymphoma

BetaCat Pharmaceuticals (**PI: Alinari**) 8/1/2016-7/31/2017
\$110,787

Exploring the activity of a novel WNT inhibitor in hematologic malignancies

ASCO Young Investigator Award (**PI: Alinari**) 7/1/2016-6/30/2017
American Society of Clinical Oncology \$50,000

Phase II trial of ibrutinib vs ibrutinib and nivolumab in relapsed/refractory Hodgkin's Lymphoma

We propose to conduct a randomized phase II study of ibrutinib vs ibrutinib + nivolumab in patients with relapsed/refractory HL following ASCT in order to select the most promising regimen as evaluated by CR and other factors.

LRF Scholar (**PI: Alinari**) 1/15/2016-5/15/2018
Lymphoma Research Foundation \$10,000

Mentored career development award for junior faculty/advanced fellows dedicated to clinical research methods and design, statistical analysis, correlative studies for clinical trials in lymphoid malignancies.

Completed

AACR Basic Cancer Research Fellowship (PI: Alinari) 7/1/2014-6/30/2015
\$50,000

Targeting protein arginine methyltransferase 5 in mantle cell lymphoma
To characterize PRMT5-driven epigenetic and signaling mechanisms that contribute to cell growth dysregulation in MCL and to utilize in vivo preclinical models of MCL to explore novel experimental therapeutic strategies.

ASH-European Hematology Association International Award (PI: Alinari) 6/2008-6/2010
\$75,000

Role of PRMT5 overexpression in B-cell lymphomagenesis

Italian Society of Experimental Haematology Award (PI: Alinari) 12/2006-12/2007
Euro 15,000

Role of PRMT5 overexpression in B-cell lymphomagenesis

Ad Hoc Manuscript Reviewer:

- Blood (2013-present)
- Haematologica (2015-present)
- Oncotarget (2015-present)
- Hematological Oncology (2016-present)

Publications:

Chapters in Books:

1. Alinari L, Porcu P, Coiffier B. Monoclonal Antibodies Therapy for T-cell Lymphomas. In: Foss FM, ed. T-cell Lymphomas. Humana Press; 2012

Reviews (peer reviewed):

1. Maly J, Alinari L. Pembrolizumab in Classical Hodgkin's Lymphoma. **European Journal of Haematology**. 2016 Sep;97(3):219-27. PMID: 27147112
2. Alinari L, Blum KA. How I treat relapsed classical Hodgkin Lymphoma after autologous stem cell transplant. **Blood**. 2016 Jan 21;127(3):287-295. PMID: 26576863
3. Alinari L, Quinion C, Blum K. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. **Clin Pharmacol Ther**. 2015 May;97(5):469-477. PMID: 25670208
4. Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. **Oncotarget**. 2012 Feb;3(2):203-11. PMID: 22361516
5. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. **Blood**, 2010 Nov 11;116(19):3705-14. PMID: 20610811

6. Erter J, **Alinari L**, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P. New Targets of Therapy in T-Cell Lymphomas. **Curr Drug Targets**, 2010 Apr;11(4):482-93. PMID: 20196721
7. **Alinari L**, Lapalombella R, Andritsos L, Baiocchi RA, Lin T, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of Chronic Lymphocytic Leukemia. **Oncogene**, 2007 May 28;26(25):3644-53. PMID: 17530018

Non-peer reviewed journal articles:

1. **Alinari L**. Toward autophagy-targeted therapy in lymphoma. **Blood**. 2017 Mar 30;129(13):1740-1742. PMID: 28360356

Peer reviewed journal articles:

1. **Alinari L**, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA. De novo CD5+ Diffuse Large B-cell Lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. **Am J Hematol**. 2016 Jun;91(4):395-399. PMID 26800311
2. Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, **Alinari L**, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi R, Marcucci G. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. **Leukemia**. 2016 April 30;30(4):789-799. PMID 26536822
3. **Alinari L**, Mahasenani KV, Yan F, Karkhanis V, Chung J-H, Smith EM, Quinion Q, Smith PL, Kim L, Patton JT, Lapalombella R, Yu B, Wu Y, Roy S, De Leo A, Pileri S, Agostinelli C, Ayers L, Bradner JE, Chen-Kiang S, Elemento O, Motiwala T, Majumder S, Byrd JC, Jacob S, Sif S, Li C, Baiocchi RA. Selective inhibition of Protein Arginine Methyltransferase 5 blocks initiation and maintenance of B-cell transformation. **Blood**. 2015 Apr 16;125(16):2530-43. PMID:25742700
4. Yan F, **Alinari L**, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell E, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon C-H, Byrd JC, Chiocca A, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. **Cancer Research**. 2014 Mar 15;74(6):1752-65. PMID:24453002
5. **Alinari L**, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. **Clin Cancer Res**. 2012 Sep 1;18(17):4600-11. PMID:22791882
6. **Alinari L**, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RA. Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male. **Head Neck Pathol**. 2012 Dec;6(4):496-501. PMID:22711054
7. **Alinari L**, Baiocchi RA, Prætorius-Ibba M. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: Is FTY720 the next autophagy-blocking agent in lymphoma treatment? **Autophagy**. 2012 Mar 1;8(3). PMID: 22377620

8. **Alinari L**, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. **Blood**. 2011 Dec 22;118(26):6893-903. PMID: 22042694
9. **Alinari L**, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Praetorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. **Blood**. 2011 Apr 28;117(17). PMID: 21228331
10. Baiocchi RA, **Alinari L**, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell lymphoma and follicular lymphoma. **Cancer**. 2010 Dec 14. PMID: 21157957
11. Lucas DM, **Alinari L**, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen CS, Baiocchi RA, Byrd JC. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. **PLoS One**. 2010 Jun 3;5(6):e10941. PMID: 20532179
12. Liu Q*, **Alinari L***, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. **Clin Cancer Res**. 2010 Jun 15;16(12):3182-92. PMID: 20460491.
*contributed equally.
13. Majumder S, **Alinari L**, Roy S, Miller T, Datta J, Sif S, Baiocchi R, Jacob ST. Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription. **J Cell Biochem**. 2010 Feb 15;109(3):553-63. PMID: 19998411.
14. **Alinari L**, White VL, Earl CT, Ryan T, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA. Combination Bortezomib and Rituximab Treatment Affects Multiple Survival and Death Pathways to Promote Apoptosis in Mantle Cell Lymphoma. **mAbs** 2009 Jan;1(1):31-40. PMID: 20046572.
15. Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, **Alinari L**, Capitani S, Miscia S, Marchisio M. Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. **Cell Res**. 2009 Sep;19(9):1079-89. PMID: 19564891.
16. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi M, Fina M, Ambrosini V, Pellegrini C, **Alinari L**, Derenzini E, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. **J Clin Oncol**. 2009 Apr 10;27(11):1781-7. PMID: 19273712.
17. Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, **Alinari L**, Venturini F, Gandolfi L, Baccarani M, Zinzani PL. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. **Cancer**. 2008 Nov 1;113(9):2496-503. PMID: 18833583.
18. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, **Alinari L**, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. **Ann Oncol**. 2008 Apr;19(4):769-73. PMID: 18303033.

19. **Alinari L**, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. **Leuk Res.** 2008 Aug;32(8):1299-303. PMID: 18096224.
20. Fina M, Tani M, Stefoni V, Musuraca G, Marchi E, Pellegrini C, **Alinari L**, Derenzini E, Bacci F, Pileri S, Baccarani M, Zinzani PL. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. **Leuk Lymphoma.** 2007 Nov;48(11):2167-71. PMID: 17990178.
21. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, **Alinari L**, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. **J Clin Oncol.** 2007 Aug 20; 4293-7. PMID: 17709797.
22. Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, Castellucci P, Musuraca G, Dalpiaz G, **Alinari L**, Marchi E, Fina M, Pellegrini C, Farsad M, Cancellieri A, Busca A, Canini R, Pileri S, Baccarani M, Boaron M. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. **Haematologica.** 2007 Jun;92(6):771-7. PMID: 17550849.
23. Zinzani PL, Musuraca G, **Alinari L**, Fanti S, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Castellucci P, Farsad M, Baccarani M. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. **Clin Lymphoma Myeloma.** 2007 Jan; 7(4):291-5. PMID: 17324337.
24. **Alinari L**, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, Berkowitz A, Tani M, Farsad M, Franchi R, Fanti S, Zinzani PL. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. **Leuk Lymphoma.** 2006 Oct; 47(10):2096-101. PMID: 17071482.
25. **Alinari L**, Ambrosini V, Castellucci P, Tani M, Stefoni V, Nanni C, Farsad M, Rubello D, Franchi R, Zinzani PL, Fanti S. Discordant response to chemotherapy: an unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pretreated lymphoma patients. **Leuk Lymphoma.** 2006 Jun;47(6):1048-52. PMID: 16840196.
26. Zinzani PL, Tani M, Fanti S, **Alinari L**, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. **Ann Oncol.** 2006 Aug;17(8):1296-300. PMID: 16766583.
27. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, **Alinari L**, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG; Italian Study Group for Cutaneous Lymphomas. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. **J Clin Oncol.** 2006 Mar 20;24(9):1376-82. PMID: 16492713.
28. Stefoni V, **Alinari L**, Musuraca G, Tani M, Marchi E, Gabriele A, Fina M, Pileri S, Baccarani M, Zinzani PL. Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. **Leuk Lymphoma.** 2005 Dec;46(12):1839-41. PMID: 16263591.
29. **Alinari L**, Musuraca G, Tani M, Stefoni V, Gabriele A, Marchi E, Fina M, De Vivo A, Pileri S, Baccarani M, Zinzani PL. Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. **Leuk Lymphoma.** 2005 Oct;46(10):1437-40. PMID: 16252433.
30. Marchi E, **Alinari L**, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. **Cancer.** 2005 Dec 1;104(11):2437-41. PMID: 16216001.

31. Zinzani PL, Tani M, **Alinari L**, Molinari AL, Stefoni V, Visani G, Gentilini P, Guardigni L, Fina M, Baccarani M. Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. **Leuk Lymphoma**. 2005 Oct;46(10):1449-54. PMID: 16194890.
32. Tani M, Fina M, **Alinari L**, Stefoni V, Baccarani M, Zinzani PL. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. **Haematologica**. 2005 Sep;90(9):1283-4. PMID: 16154858.
33. Castellucci P, Nanni C, Farsad M, **Alinari L**, Zinzani P, Stefoni V, Battista G, Valentini D, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Franchi R, Rampin L, Fanti S, Rubello D. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. **Nucl Med Commun**. 2005 Aug;26(8):689-94. PMID: 16000986.
34. Zinzani PL, **Alinari L**, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. **Haematologica**. 2005 May;90(5):702-3. PMID: 15921394.
35. Castellucci P, Zinzani P, Pourdehnad M, **Alinari L**, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S. 18F-FDG PET in malignant lymphoma: significance of positive findings. **Eur J Nucl Med Mol Imaging**. 2005 Jul;32(7):749-56. PMID: 15785956.
36. Zinzani PL, Dirnhofer S, Sabattini E, **Alinari L**, Piccaluga PP, Stefoni V, Tani M, Musuraca G, Marchi E, Falini B, Baccarani M, Pileri SA. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. **Haematologica**. 2005 Mar;90(3):341-7. PMID: 15749666.
37. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, Rizzi S, Giudice V, Farese O, Rovito M, **Alinari L**, Conte R, Baccarani M, Lemoli RM. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. **Haematologica**. 2005 Feb; 90 (2): 225-31. PMID: 15710576.
38. Castellucci P, Zinzani P, Nanni C, Farsad M, Moretti A, **Alinari L**, Battista G, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Fanti S. 18F-FDG PET early after radiotherapy in lymphoma patients. **Cancer Biother Radiopharm**. 2004 Oct;19(5):606-12. PMID: 15650453.
39. Zinzani PL, **Alinari L**, Stefoni V, Loffredo A, Pichierri P, Polito E. Rituximab in primary conjunctiva lymphoma. **Leuk Res**. 2005 Jan;29(1):107-8. PMID: 15541482.
40. Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, **Alinari L**, Farsad M, Musuraca G, Gabriele A, Marchi E, Nanni C, Canini R, Monetti N, Baccarani M. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. **Br J Cancer**. 2004 Aug 31;91(5):850-4. PMID: 15266320.
41. Zinzani PL, Pulsoni A, Gentilini P, Visani G, Perrotti A, Molinari AL, Guardigni L, Tani M, Villiva N, Stefoni V, **Alinari L**, Martelli M, Bonifazi F, Pileri S, Tura S, Baccarani M. Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. **Leuk Lymphoma**. 2004 Sep;45(9):1815-9. PMID: 15223641.
42. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, **Alinari L**, Martelli M, Pileri S, Tura S, Baccarani M. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. **J Clin Oncol**. 2004 Jul 1;22(13):2654-61. PMID: 15159414.

43. Zinzani PL, Stefoni V, Musuraca G, Tani M, **Alinari L**, Gabriele A, Marchi E, Pileri S, Baccarani M. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. **Cancer**. 2004 May 15;100(10):2190-4. PMID: 15139063.
44. Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, **Alinari L**, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. **Leuk Lymphoma**. 2004 Feb;45(2):321-6. PMID: 15101718.
45. Zinzani PL, Tani M, Marchi E, Stefoni V, **Alinari L**, Musuraca G, Gabriele A, Pileri S, Baccarani M. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. **Haematologica**. 2004 Mar;89(3):309-13. PMID: 15020269.
46. Zinzani PL, Stefoni V, **Alinari L**, Vianelli N, Baccarani M. Rituximab in heavily pretreated cutaneous B-cell lymphoma. **Leuk Lymphoma**. 2003 Sep;44(9):1637-8. PMID: 14565673.
47. Zinzani PL, Tani M, Barbieri E, Stefoni V, **Alinari L**, Baccarani M. Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma. **Haematologica**. 2003 Jul;88(7):830-1. PMID: 12857565.
48. Zinzani PL, Tani M, Gabriele A, Poletti V, Stefoni V, **Alinari L**, Musuraca G, Bonifazi F, Pileri S, Tura S, Baccarani M. Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. **Leuk Lymphoma**. 2003 May;44(5):821-4. PMID: 12802920.
49. Zinzani PL, **Alinari L**, Stefoni V, Tani M, Baccarani M. Bilateral primary breast lymphoma: a case of local recurrence. **Leuk Lymphoma**. 2003 Apr;44(4):737-8. PMID: 12769356.
50. Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Giudice V, Zompatori M, Stefoni V, **Alinari L**, Musuraca G, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. **Haematologica**. 2003 May;88(5):522-8. PMID: 12745271.
51. Zinzani PL, Carrillo G, Ascani S, Barbieri E, Tani M, Paulli M, Stefoni V, Sabattini E, **Alinari L**, Binazzi R, Tura S, Baccarani M, Pileri SA. Primary bone lymphoma: experience with 52 patients. **Haematologica**. 2003 Mar;88(3):280-5. PMID: 12651266.
52. Zinzani PL, Tani M, **Alinari L**, Stefoni V, Baccarani M. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire? **Leuk Res**. 2003 May;27(5):465-6. PMID: 12620298.
53. Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, **Alinari L**, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. **Haematologica**. 2002 Dec;87(12):1258-64. PMID: 12495899.
54. Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, **Alinari L**, Baccarani M, Tura S. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. **Ann Oncol**. 2002 Sep;13(9):1364-9. PMID: 12196361.

55. Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, **Alinari L**, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. **Haematologica**. 2002 Aug;87(8):816-21. PMID: 12161357.
56. Zinzani PL, Chierichetti F, Zompatori M, Tani M, Stefoni V, Garraffa G, Albertini P, **Alinari L**, Ferlin G, Baccarani M, Tura S. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. **Leuk Lymphoma**. 2002 Jun;43(6):1239-43. PMID: 12152991.
57. Zinzani PL, Stefoni V, Tani M, Barbieri E, Albertini P, Vigna E, Gherlinzoni F, **Alinari L**, Galuppi A, Pileri S, Babini L, Tura S. MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. **Leuk Lymphoma**. 2001 Sep-Oct;42(5):989-95. PMID: 11697654.
58. Zinzani PL, Tani M, Stefoni V, Albertini P, Bendandi M, Gherlinzoni F, **Alinari L**, Vigna E, Tura S. Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. **Haematologica**. 2001 Mar;86(3):287-90. PMID: 11255276.

Abstracts (since joining faculty):

1. Smith, P, Yan F, Patton JT, **Alinari L**, Karkhanis V, Ayers L, Muthusamy N, Mishra A, Ahmed E, Sif S, Lapalombella R, and Baiocchi RA. PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas. Presented at the 2016 American Society of Hematology Meeting. Abstract 2936.
2. Karkhanis V, **Alinari L**, Mundy B, Caliguri M, Chen-Kiang S, Elemento O, Said S, Baiocchi RA. PRMT5 Targets Tumor Suppressor Micro RNAs to Regulate Cyclin D1 and c-MYC in Mantle Cell Lymphoma. Presented at the 2016 American Society of Hematology Meeting. Abstract 2937.

Oral Presentations (invited speaker):

International:

1. 4th International Conference Translational Research in Oncology. Forli', Italy, November 9-11, 2016, *Targeting BTK in lymphoid malignancies.*
2. 53rd Annual Meeting of American Society of Hematology. San Diego, CA, USA, December 10-13, 2011. *FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death*
3. 50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, December 6-9, 2008 *Combination anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy has In Vitro and In Vivo Activity in Mantle Cell Lymphoma*
4. New Drugs in Hematology. Bologna, Italy, October 9-11, 2005. *Gemcitabine (Gemzar): from solid tumors to hematologic malignancies*

5. 5th International Symposium on Special Aspects of Radiotherapy.
Berlin, Germany, May 9-11, 2000.
Neoadjuvant Hormonotherapy (NHT) and Radiotherapy (RT) in Prostatic Cancer

National:

1. Association of Professors of Medicine, Winter Meeting, Charleston, South Carolina, February 26th, 2016.
Research-Based Schools “Physician Scientists Needed: Focus on PSTP – New Pathways & New Programs”.
2. Successful Research Panel, The Ohio State University, Medical Student Research Orientation. Columbus, Ohio, May 13th, 2015.
3. Cancer patients and fertility. Ravenna, Italy, November 11th, 2005.
Lymphoma treatment options in young patients.
4. Observations in Hematology. Mestre, Italy, June 24th, 2005.
Monoclonal antibodies in the treatment of B-cell Chronic Lymphocytic Leukemia: “Campath-Rituximab-Zevalin”.
5. Neuro-oncology - 2^o Symposium. Turin, Italy, May 23-27, 2005.
Non-Hodgkin’s Lymphomas with central nervous system (CNS) involvement.
6. Non-Hodgkin’s Lymphomas and minimal residual disease: diagnosis and treatment. Naples, Italy, December 13-14, 2004.
Role of Monoclonal Antibodies in the treatment of minimal residual disease.
7. Cutaneous Lymphomas: Dermatology or Hematology? Cervia, (Ravenna), Italy, October 2nd, 2004.
New drugs development for the treatment of Cutaneous Lymphomas: an update.
8. Future Directions in Onco-Hematology. Palermo, Italy, June 18-19, 2004.
Gastrointestinal Non Hodgkin’s Lymphomas.
9. 79^o National Meeting of the Italian Society of Dermatology and Sexually Transmitted Diseases (SIDEMaST). Castellaneta Marina (Taranto), Italy, May 26-29, 2004.
Cutaneous Lymphomas: old and new drugs.
10. Neuro-oncology - 1^o Symposium. Turin, Italy, May 20th, 2004.
Primary central nervous system (CNS) lymphomas. Radiotherapy and chemotherapy.
11. Italian Association of Radiation Oncology (AIRO). Palermo, Italy, November 29th, 2003.
Immunotherapy with naked and radio-conjugated monoclonal antibodies in Non-Hodgkin’s Lymphomas.
12. Italian Society of Hematology (SIE). Rome, Italy, October 27th, 2003.

Front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine: long-term outcome.

13. Non-Hodgkin's Lymphomas in elderly patients. Milan, Italy, November 12th, 2002.
High-grade Non-Hodgkin's Lymphomas in elderly patients.
14. Annual Meeting of Oncology. Bentivoglio, (Bologna), Italy, October 9-11, 2000.
Role of radiotherapy in relapsed breast cancer patients.
15. Annual Meeting of Oncology. Bentivoglio, (Bologna), Italy, October 9-11, 2000.
Thromboembolism in cancer patients: preliminary results of a retrospective multicenter national study.